Title: Oxymatrine Capsule Plus Thymosin α-1 for Chronic Hepatitis B:Observation of Curative Efficacy
Abstract: OBJECTIVE:To observe the efficacy and safety of Oxymatrine capsule plus Thymosin α 1 in the treatment of chronic hepatitis B(CHB).METHODS:Of the total 60 patients with CHB,28(trial group) were randomly assigned to receive Oxymatrine capsule orally(at a dose of 0.3g· time-1 tid,2mon later,reduced to 0.2g· time-1 tid),and 32(control group) to receive interferon α-2b500MU by intramuscular injection q.d but shifted to EOD 1 month later.All the patients were treated for 24wk and followed for additional 48wk.The ALT recovery rate,HBV-DNA negative changing rate,HBeAg negative changing rate,and seroconversion rate were compared between the two groups.RESULTS:At 12 and 24 weeks' treatment,there were no significant differences between the 2 groups in ALT recovery rate,HBV-DNA negative changing rate,HBeAg negative changing rate,and seroconversion rate(P0.05).At 24 and 48 weeks' follow-up,ALT recovery rates of 64.3% vs.71.4% achieved in the trial group,and 34.4% vs.43.8% in the control group,showing significant differences between the two groups(P0.05),seroconversion rates of 42.8% vs.46.4% achieved in the trial group,and 25.0% vs.21.9% in the control group,showing significant differences between two groups(P0.05) ;At 48 weeks' follow-up,HBeAg negative changing rates of 50.0% achieved in trial group,and 25.0% in the control group,showing significant differences between the two groups(P0.05).CONCLUSION:The combined therapy of Oxymatrine capsule plus Thymosin α-1 was proved to be convenient and safe to use in treating chronic hepatitis B,and which showed significant inhibition on the replication of hepatitis B virus and to which patients had a sustained response.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot